Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Name Risk Assessments Should Be Conducted By Manufacturers, FDA Says

Executive Summary

Drug and biologic sponsors should conduct a risk assessment on the product's name, labeling and packaging to minimize medication errors, an FDA concept paper states

You may also be interested in...



Post-Marketing Safety Surveillance Should Include Data Mining, FDA Says

FDA proposes data mining as one technique useful for drawing connections between products and adverse events in a draft guidance on post-marketing safety surveillance

Post-Marketing Safety Surveillance Should Include Data Mining, FDA Says

FDA proposes data mining as one technique useful for drawing connections between products and adverse events in a draft guidance on post-marketing safety surveillance

Drug Name Errors Workshop Will Focus On Study Design Of Premarket Tests

An FDA public meeting on drug name errors will focus on how to design premarket trials to detect potential problems

Related Content

UsernamePublicRestriction

Register

PS041407

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel